Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Invitation to SAS’ Q2 2021 teleconference

SAS will publish the interim report for the second quarter of the fiscal year 2021 on Thursday, 27 of May 2021, at approximately 08.00 AM (CET). A teleconference and webcast for investors, analysts and media will be held at 10.00 AM (CEST). Karl Sandlund, acting President & CEO and Magnus Örnberg, Executive Vice President & CFO will present and comment the report. The presentation will be held in English via telephone or https://www.sasgroup.net No advance notification is necessary. Dial-in details for the conference call: DK: +45 354 455 77 FI: +358 981 710 310 NO: +47 235

Kojamo Plc: Flagging notification in accordance with Chapter 9, Section 10 of the Securities Markets Act

Kojamo Plc Stock Exchange Release, 25 May 2021 at 12:00 noon EESTFlagging notification in accordance with Chapter 9, Section 10 of the Securities Markets Act Kojamo plc (the "Company") has on 25 May 2021 received a notification pursuant to Chapter 9, Section 5 of the Securities Markets Act from Teollisuusliitto Ry. According to the notification, the holding of Teollisuusliitto Ry in the Company's shares and votes has fallen below 10 per cent on 24 May 2021. This company holds a total of 24,409,561 shares corresponding to an ownership of 9.87664 percent. Total position of

Valokuitunen secures strong lender financing for roll-out of fibre networks in Finland

CapMan Infra press release 25 May 2021 at 12.00 noon EEST Valokuitunen secures strong lender financing for roll-out of fibre networks in Finland Valokuitunen Oy, a joint venture between CapMan Infra and Telia, has secured 5-year loan facilities with Skandinaviska Enskilda Banken (SEB) and Nordic Investment Bank (NIB) for financing the roll-out of new fibre-to-the-home network connections in Finland. The financing will continue to support Valokuitunen’s investments into new digital infrastructure and services, and expand the coverage of high-speed fixed line connections in

Inhalation Sciences signs exclusive distribution agreement with Sanyo Trading, Japan

(Stockholm, Sweden, May 25, 2021) The agreement grants Sanyo Trading exclusive sales rights to ISAB instruments in Japan, with a minimum purchasing commitment of 3 000 000 SEK in 2021 and a minimum of 5 000 000 SEK in 2022.ISAB has significantly strengthened its global sales strategy recently, with increased activities in the US and the signing of a new distribution agreement covering India, Bangladesh and Sri Lanka. Japan is a key target market for ISAB, with a large population, a robust research sector, advanced technology and strong pricing levels. Founded in 1947, Sanyo Trading is

BioStock: Iconovo's high aiming business goals

Last week, Iconovo announced its financial targets for 2026. In five years, the company expects to have ten projects in development and five launched inhalation products that generate royalties. In addition, the goal is to enter into 1 – 3 new customer agreements per year on the way there. All in all, this is expected to generate sales of 200 million SEK and an operating profit of 100 million SEK in 2026. Iconovo also sees two potential upsides: royalty revenue from innovative inhalation products as well as from royalty revenue from generic Symbicort in the US.Read the full article at

Medivir to present at the ABGSC Life Science Summit

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) announces that the company will present at the virtual meeting ABGSC Life Science Summit, today, May 25. The company will be represented by Magnus Christensen, interim CEO, and Fredrik Öberg, Chief Scientific Officer. The presentation will be available after the seminar on Medivirs website; www.medivir.com. For additional information, please contactMagnus Christensen, interim CEO and CFOTelephone: +46 8 5468 3100E-mail: magnus.christensen@medivir.com  Medivir in briefMedivir develops innovative drugs with a focus on

KEBNI RELEASES QUARTERLY REPORT FOR Q1 2021, JANUARY-MARCH

Stockholm, 25 May 2021 Events January-March 2021 · On February 1, Torbjörn Saxmo took over as the new CEO of KebNi. · At the beginning of March, KebNi carried out a directed new share issue that brought in approximately SEK 12,141,000, and KebNi thus gained a long-term major shareholder. · At the end of March, KebNi carried out a directed new share issue that brought in approximately SEK 26,220,000, thereby securing several more long-term major shareholders and strengthening capital for the year. Key figures · Net sales amounted to 1,788 (14,100) KSEK · Operating profit

SimCorp A/S – Share buyback program

Company Announcement no. 22/2021On February 10, 2021 SimCorp A/S announced a share buyback program in compliance with the provisions of Regulation No. 596/2014 of the European Parliament and of the Council on market abuse (the Market Abuse Regulation - MAR) and delegated legislation under MAR. In connection with the program SimCorp A/S will repurchase shares for an amount of up to EUR 20.0m, to be executed during the period from February 10, 2021 to July 31, 2021. The following transactions have been executed under the program:          Date                 Number of shares

Isofol publishes prospectus in connection with the fully guaranteed preferential rights issue of approximately SEK 400 million

GOTHENBURG, Sweden, May 25, 2021 - Isofol Medical AB’s (publ), (Nasdaq First North Premier Growth Market: ISOFOL), (“Isofol or the “Company”) Board of Directors resolved on May 18, 2021, on an issue of shares of a maximum of 62,524,474 shares with preferential rights for the Company’s existing shareholders (the “Rights Issue”). If the Rights Issue is fully subscribed, the Company will receive approximately SEK 400 million before transaction costs related to the Rights Issue. In connection with the Rights Issue, the Company publishes a prospectus which today has been approved and registered by

OrganoClick presents at ABG Sundal Colliers Investor days

OrganoClicks will via its CEO Mårten Hellberg participate in ABG Sundal Colliers Investor Days on May 26, which will be broadcast digitally. Follow the presentation on OrganoClick's development with special focus on planned expansion of production made possible by the recently completed private placement. Time: May 26, 5: 00-5: 30 p.m. Location: www.introduce.se Link to OrganoClick's presentation starting at 17:00 is https://www.youtube.com/watch?v=Eh_TJeV2-zk Investor Days is organized by ABG Sundal Colliers via the Introduce platform. The presentation is followed by question

Company Announcement No. 50, 2021 – Debtor composition in Nordea Kredit (CK 92)

Monthly information on debtor composition in Nordea Kredit published in order to comply with the Transparency Directive's disclosure requirements.Nordea Kredit hereby publishes monthly data on debtor composition of all callable bond series. The information is subject to disclosure requirements in the Securities Trading Act § 27a section 1.The information is also published in the usual way via the Copenhagen Stock Exchange / OMX. Nordea Kredit Realkreditaktieselskab Bo Dam Klausen Phone : +45 55 47 31 42

IRLAB’s drug candidate mesdopetam’s Phase I results published in scientific journal PR&P

IRLAB (Nasdaq Stockholm: IRLAB A) announced today that a scientific paper reporting the clinical phase I study results for drug candidate mesdopetam has been published in the journal Pharmacology Research & Perspectives (PR&P). Mesdopetam is a dopamine D3 receptor antagonist and is currently being evaluated in an international Phase IIb/III study for the treatment of levodopa-induced dyskinesias (LIDs) in Parkinson’s disease.The scientific paper describes the prospective, single-center, randomized, double-blind, placebo-controlled phase I, first-in-human (FIH) study with mesdopetam. The

Nobina secures large procurement contracts in Helsinki

Nobina Finland will begin operating a total of four contracts in Helsinki, of which one is completely new to Nobina. The four contracts represent a total turnover of approximately EUR 207 million over the contract period of seven years, and involve a total of 122 scheduled buses, of which most are electric buses. Traffic is scheduled to start in August 2022.The Helsinki Regional Transport Authority (HSL) has awarded Nobina expanded and renewed contracts to operate public transport services in the Helsinki region. Nobina has also been entrusted to operate services as part of one completely

Pexip - increase of share capital following exercise of employee share options

Oslo, May 25, 2021: Following vesting and exercise of previously issued employee options, the Board of Directors of Pexip Holding ASA ("Pexip" or the "Company", Oslo Børs ticker "PEXIP", LEI 549300S79JFZK79XBI07) has today resolved, based on authorization granted by the Company's general meeting held on May 20, 2021, to issue 612,288 new shares for an aggregate subscription price of NOK 16,454,267.30. The shares have been subscribed for by various employee option holders. Following the issuance of the new shares, Pexip will have 104,429,671 shares outstanding, each with a nominal value of

Bulletin from Balco Group’s Annual General Meeting 2021

Växjö 25 May 2021In light of the risk of the spread of the virus causing Covid-19, the Annual General Meeting of Balco Group AB ("Balco" or "the Company") was conducted on Tuesday 25 May 2021 solely through advance voting (so-called postal voting) pursuant to temporary rules. The Annual General Meeting approved the Company’s and the group’s profit and loss statements and granted the members of the Board of Directors and the CEO discharge from liability for the financial year 2020. The Annual General Meeting resolved, in accordance with the proposal made by the Board of Directors, to

The AniCura Research Fund celebrates over 60 clinical research projects during its first five years

By gathering leading veterinary competence, and focusing on continuous development of quality and service, AniCura’s vision is to shape the future of veterinary care. Hence, The AniCura Research Fund plays a vital role in advance clinical research in the industry. Since 2015, over 60 clinical research projects have been granted funding. As of 2019, AniCura's Research Fund has doubled in size, by support of Mars Veterinary Health.– Continuous development, and specialization among our 2,800 veterinarians have always been in focus for AniCura. It helps us to provide the highest possible

Christopher Norbye appointed CEO of Beijer Ref

The Board of Directors of Beijer Ref AB (publ) has today appointed Christopher Norbye as new CEO and President of Beijer Ref. Christopher Norbye is currently Executive Vice President and Head of Entrance Systems Division at Assa Abloy. Christopher is expected to start in his new position during the fourth quarter. The appointment follows the decision by Per Bertland, announced on 27 January 2021, to step down as CEO of Beijer Ref when a successor has been found or during the latter part of 2021 at the latest. Kate Swann, Chairman of the Board of Directors, says: “With Christopher

2020 Bulkers Ltd. – Circulates Request for Written Resolution of Shareholders

Hamilton, Bermuda, May 25[th], 2021 2020 Bulkers Ltd. (the “Company”) has today distributed to its shareholders a request for approval by resolution in writing, inter alia, to reduce the Company’s Share Premium account from US$120,232,597 to US$105,232,597.  A copy of the Notice, Information Statement and Written Resolutions are attached.  The request is made to its shareholders with shares registered on the record date May 21[st], 2021. For further queries, please contact:  Magnus Halvorsen, Chief Executive Officer, 2020 Bulkers Management AS  Telephone +47 920 20 111

Citycon Oyj considers issuance of green Capital Securities

CITYCON OYJ   Inside information   25 May 2021 at 10:30 hrsNOT TO BE RELEASED, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART IN OR INTO OR TO ANY PERSON LOCATED IN OR RESIDENT IN THE UNITED STATES, ITS TERRITORIES AND POSSESSIONS, ANY STATE OF THE UNITED STATES OR THE DISTRICT OF COLUMBIA (TOGETHER THE "UNITED STATES"), AUSTRALIA, CANADA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL.Citycon Oyj (“Citycon”) is considering the issuance of euro-denominated green capital securities (“Capital Securities”) in an amount of

BioStock: Invent strengthens patent portfolio with new US approval

The Lund-based medtech company Invent Medic, which develops products that aim to improve women’s health, has received patent approval in the US for Efemia bladder support. The approval, which applies to the current version of the product, further strengthens the company’s patent and design protection portfolio.Read the full article at biostock.se: https://www.biostock.se/en/invent-strengthens-patent-portfolio-with-new-us-approval/This is a press release from BioStock - Connecting Innovation & Capital.https://www.biostock.se

Risk Intelligence A/S signs an agreement for the Risk Intelligence System with a leading engineering and technology company.

Risk Intelligence A/S (“Risk Intelligence” or "the Company") announces today that the company has signed an agreement with a leading technology and engineering company for the Risk Intelligence System.The company is a leader in engineering and technology solutions for the energy industry, employing cutting edge technology at the forefront of energy transition including biofuels, LNG and renewables. Jim Pascoe, Chief Commercial Officer of Risk Intelligence, says:“Their worldwide presence and diverse activities make them an ideal client for us, and we are really looking forward to

Scandinavian ChemoTech remains positive to CE marking despite absent response before deadline

Due to the large number of accumulated applications that all control bodies experience, we do not know for sure if the result will come before 26 May. Despite the lack of a response to the Company's CE marking application, ChemoTech remains positive.At present, all control bodies are struggling to process the final phase of all applications for CE markings under the current MDD regulations, which is a regulatory and strict process without shortcuts. “We know that many shareholders are eagerly awaiting the statement on ChemoTech's CE marking of the IQwave™ and our TSE technology.

There are no items matching the current filter
There are no more items matching the current filter
Back to top